Peter Westervelt

62.1k total citations
195 papers, 5.7k citations indexed

About

Peter Westervelt is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Peter Westervelt has authored 195 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Hematology, 47 papers in Molecular Biology and 42 papers in Oncology. Recurrent topics in Peter Westervelt's work include Acute Myeloid Leukemia Research (95 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Acute Lymphoblastic Leukemia research (39 papers). Peter Westervelt is often cited by papers focused on Acute Myeloid Leukemia Research (95 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Acute Lymphoblastic Leukemia research (39 papers). Peter Westervelt collaborates with scholars based in United States, Canada and United Kingdom. Peter Westervelt's co-authors include John F. DiPersio, Ravi Vij, Lee Ratner, Geoffrey L. Uy, Timothy J. Ley, Keith Stockerl‐Goldstein, Howard E. Gendelman, Camille N. Abboud, Michael P. Rettig and Amanda F. Cashen and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Peter Westervelt

190 papers receiving 5.6k citations

Peers

Countries citing papers authored by Peter Westervelt

Since Specialization

Citations

This map shows the geographic impact of Peter Westervelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Westervelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Westervelt more than expected).

Fields of papers citing papers by Peter Westervelt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Westervelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Westervelt. The network helps show where Peter Westervelt may publish in the future.

Co-authorship network of co-authors of Peter Westervelt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Westervelt. A scholar is included among the top collaborators of Peter Westervelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Westervelt. Peter Westervelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102 2024 ·JCO Oncology Practice ·Wael Saber, Aasthaa Bansal, (unknown), Bart L. Scott, Lindsey R. Sangaralingham, Viengneesee Thao, Joshua A. Roth, (unknown), Lotte Steuten, Joseph A. Pidala, Asmita Mishra, Richard T. Maziarz, Peter Westervelt, Joseph P. McGuirk, Corey Cutler, Ryotaro Nakamura, Scott D. Ramsey	6
2	Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma 2023 ·Blood Advances ·Armin Ghobadi, (unknown), (unknown), Michael P. Rettig, Amanda F. Cashen, Leah Gehrs, Stephanie Christ, (unknown), Nicholas A. Wallace, Julie Ritchey, Neha Mehta–Shah, Peter Westervelt, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, John F. DiPersio	6
3	Genomic landscape of TP53-mutated myeloid malignancies 2023 ·Blood Advances ·Haley Abel, Karolyn A. Oetjen, Christopher A. Miller, Sai Mukund Ramakrishnan, Ryan B. Day, Nichole Helton, Catrina C. Fronick, Robert S. Fulton, Sharon E. Heath, (unknown), Sridhar Nonavinkere Srivatsan, Eric J. Duncavage, Molly C. Schroeder, Jacqueline E. Payton, David H. Spencer, Matthew J. Walter, Peter Westervelt, John F. DiPersio, Timothy J. Ley, Daniel C. Link	15
4	Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation 2023 ·Transplantation and Cellular Therapy ·(unknown), Jaebok Choi, Matthew Cooper, (unknown), Mark A. Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda F. Cashen, Meagan A. Jacoby, Keith Stockerl‐Goldstein, Camille N. Abboud, Ravi Vij, Geoffrey L. Uy, Peter Westervelt, Matthew J. Walter, John F. DiPersio, Mark A. Schroeder	2
5	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud, Feng Gao, Michael P. Rettig, (unknown), Leah Gehrs, Nicholas A. Wallace, Camille N. Abboud, Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matthew Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder	1
6	Mutation Analysis in Patients with High-Risk Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Cell Transplantation Based on Biological Donor Availability: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 2022 ·Transplantation and Cellular Therapy ·Jurjen Versluis, Wael Saber, Harrison Tsai, Christopher J. Gibson, Asmita Mishra, Joseph P. McGuirk, Richard T. Maziarz, Peter Westervelt, (unknown), (unknown), Brent R. Logan, Mary M. Horowitz, Ryotaro Nakamura, Corey Cutler, R. Coleman Lindsley	1
7	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease 2021 ·Blood ·Iskra Pusic, Tanner M. Johanns, Stefanie Sarantopoulos, (unknown), (unknown), Peter Westervelt, Amanda F. Cashen, Geoffrey L. Uy, Camille N. Abboud, John F. DiPersio	1
8	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product 2018 ·Blood ·Michael P. Rettig, Geoffrey L. Uy, Asad Bashey, Steven M. Devine, Samantha Jaglowski, (unknown), Ella Sorani, (unknown), Osnat Bohana‐Kashtan, Stephen Shaw, Peter Westervelt, John F. DiPersio	1
9	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen 2017 ·Cancer Medicine ·Alaa M. Ali, (unknown), Feng Gao, Geoffrey L. Uy, Amanda F. Cashen, Meagan A. Jacoby, Lukas D. Wartman, Armin Ghobadi, Iskra Pusic, Rizwan Romee, Todd A. Fehniger, Keith Stockerl‐Goldstein, Ravi Vij, Stephen T. Oh, Camille N. Abboud, Mark A. Schroeder, Peter Westervelt, John F. DiPersio, John S. Welch	21
10	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation 2017 ·Biology of Blood and Marrow Transplantation ·Yi-Shan Lee, Jingxia Liu, (unknown), (unknown), (unknown), (unknown), (unknown), Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. DiPersio, Friederike Kreisel, Kian‐Huat Lim	7
11	Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant 2017 ·Blood ·Meagan A. Jacoby, Eric J. Duncavage, Gue Su Chang, Christopher A. Miller, Jin Shao, (unknown), Joshua D. Robinson, Robert S. Fulton, Catrina C. Fronick, Michelle D. O’Laughlin, Daniel C. Link, John F. DiPersio, Peter Westervelt, Timothy J. Ley, Timothy A. Graubert, Matthew J. Walter	1
12	A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS 2017 ·Blood ·(unknown), Amanda F. Cashen, John F. DiPersio, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Geoffrey L. Uy, Peter Westervelt	3
13	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML 2016 ·Bone Marrow Transplantation ·Armin Rashidi, Michael Slade, John F. DiPersio, Peter Westervelt, Ravi Vij, Rizwan Romee	25
14	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning 2016 ·Biology of Blood and Marrow Transplantation ·Armin Rashidi, John F. DiPersio, Peter Westervelt, Camille N. Abboud, Mark A. Schroeder, Amanda F. Cashen, Iskra Pusic, Rizwan Romee	8
15	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia 2012 ·Blood ·Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi, Kyle McFarland, Kathryn Trinkaus, Lindsay Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio	310
16	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia 2010 ·Blood ·Todd A. Fehniger, Geoffrey L. Uy, Kathryn Trinkaus, (unknown), (unknown), Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Peter Westervelt, John F. DiPersio, Ravi Vij	82
17	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction 2008 ·Blood ·Steven M. Devine, Ravi Vij, Michael P. Rettig, Laura Todt, (unknown), Nicholas M. Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio	234
18	Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML) 2006 ·Cancer Research ·(unknown), Jan Černý, (unknown), (unknown), (unknown), Peter Westervelt, Naomi Galili, Azra Raza	1
19	Role of HIV-1 Envelope V3 Loop Cleavage in Cell Tropism 1993 ·AIDS Research and Human Retroviruses ·(unknown), Peter Westervelt, Lee Ratner	23
20	Formation of Noninfectious HIV-1 Virus Particles Lacking a Full-Length Envelope Protein 1991 ·AIDS Research and Human Retroviruses ·Lee Ratner, Nancy Vander Heyden, (unknown), (unknown), Peter Westervelt, Michael J. Becich	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact